LRRFIP1 Antibody (J-14): sc-101168

LRRFIP1 Antibody (J-14) is a mouse monoclonal IgG2a antibody that detects LRRFIP1 in human samples through various applications including western blotting (WB), immunoprecipitation (IP), immunofluorescence (IF), immunohistochemistry with paraffin-embedded sections (IHCP), and enzyme-linked immunosorbent assay (ELISA). LRRFIP1, also known as GCF2, is a 738 amino acid protein that plays a crucial role as a transcriptional repressor, preferentially binding to the GC-rich consensus sequence (5′-AGCCCCCGGCG-3′). This binding is significant as LRRFIP1 may regulate the expression of key growth factors such as tumor necrosis factor (TNF), epidermal growth factor receptor (EGFR), and platelet-derived growth factor A (PDGF-A), thereby influencing cellular processes like proliferation and differentiation. Notably, LRRFIP1 is involved in controlling smooth muscle cell proliferation following arterial injury through the repression of PDGF-A, highlighting LRRFIP1′s importance in vascular biology and potential implications in cardiovascular diseases. LRRFIP1′s N-terminus exhibits high homology to the coiled-coil domain of FLAP, which interacts with the leucine-rich repeat (LRR) of Flightless I, suggesting a functional link between LRRFIP1 and the actin cytoskeleton. Furthermore, LRRFIP1′s ability to bind double-stranded RNA with high affinity, while showing weak binding to double-stranded DNA, underscores LRRFIP1′s potential role in RNA metabolism and regulation within mammalian cells. The identification of the RNA binding domain, characterized by a lysine-rich motif, further emphasizes LRRFIP1′s multifaceted functions in cellular processes.

Alexa Fluor^® is a trademark of Molecular Probes Inc., OR., USA

LI-COR^® and Odyssey^® are registered trademarks of LI-COR Biosciences

LRRFIP1 Antibody (J-14) References:

1. Higher LRRFIP1 expression in glioblastoma multiforme is associated with better response to teniposide, a type II topoisomerase inhibitor.  |  Li, WQ., et al. 2014. Biochem Biophys Res Commun. 446: 1261-7. PMID: 24690174
2. Silencing of LRRFIP1 reverses the epithelial-mesenchymal transition via inhibition of the Wnt/β-catenin signaling pathway.  |  Douchi, D., et al. 2015. Cancer Lett. 365: 132-40. PMID: 26047573
3. The alternatively spliced LRRFIP1 Isoform-1 is a key regulator of the Wnt/β-catenin transcription pathway.  |  Labbé, P., et al. 2017. Biochim Biophys Acta Mol Cell Res. 1864: 1142-1152. PMID: 28322931
4. Multidisciplinary Roles of LRRFIP1/GCF2 in Human Biological Systems and Diseases.  |  Takimoto, M. 2019. Cells. 8: PMID: 30709060
5. LRRFIP1 expression triggers platelet agglutination by enhancing αIIbβ3 expression.  |  Yin, X., et al. 2019. Exp Ther Med. 18: 269-277. PMID: 31258662
6. A novel LRRFIP1-ALK fusion in inflammatory myofibroblastic tumor of hip and response to crizotinib.  |  Liu, W., et al. 2021. Invest New Drugs. 39: 278-282. PMID: 32915420
7. Silencing of LRRFIP1 enhances the sensitivity of gemcitabine in pancreatic cancer cells by activating JNK/c-Jun signaling.  |  Kawasaki, S., et al. 2021. Pancreatology. 21: 771-778. PMID: 33707114
8. LRRFIP1, an epigenetically regulated gene, is a prognostic biomarker and predicts malignant phenotypes of glioma.  |  Ma, W., et al. 2022. CNS Neurosci Ther. 28: 873-883. PMID: 35338570
9. lncRNA UCA1 regulates miR-132/Lrrfip1 axis to promote vascular smooth muscle cell proliferation.  |  Chen, W., et al. 2023. Open Med (Wars). 18: 20230738. PMID: 37533737
10. Acute myeloid leukemia with LRRFIP1::FGFR1 rearrangement and a complex karyotype.  |  Qian, YW., et al. 2023. Cancer Genet. 278-279: 50-54. PMID: 37597337

The preferred LRRFIP1 antibody is LRRFIP1 Antibody (G-4): sc-514221.